Antipodean begins phase II Parkinson’s trial

MitoQ (mitoquinone) is a compound based on a novel technology, targeted lipophilic cations, that transport and concentrate antioxidants into the mitochondria where they accumulate up to 1,000-fold. There they have been shown to significantly interrupt oxidative damage, which is implicated as a catalyst in Parkinson’s and other neurological diseases.

MitoQ was invented by Professor Robin Smith and Dr Michael Murphy, at the University of Otago in New Zealand.

The phase II trial will be led by Dr Barry Snow, head of the department of neurology at Auckland Hospital, and will involve 10 consultant neurologists at the country’s main regional hospitals who will assess and advise potential participants. Parkinson’s New Zealand, a non-profit patient information and support group, will also be involved.

Criteria for inclusion in the trial will focus on people who meet the diagnosis of Parkinson’s, but have yet to receive any treatment to relieve symptoms.